# A Monotherapy in Subjects With Advanced Solid Tumors

> **NCT04221204** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **3D Medicines (Beijing) Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** Highly selective FGFR1-3 inhibitor

## Key facts

- **NCT ID:** NCT04221204
- **Lead sponsor:** 3D Medicines (Beijing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221204, "A Monotherapy in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04221204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*